In this symposium preceding the ASH Annual Meeting on 12/4/20, the overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. The speakers will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.
ASH Clinical News speaks with Maureen Achebe, MD, MPH, Clinical Director of the Non-Malignant Hematology Clinic at Brigham and Women’s Hospital in Boston, and other experts about the safety and efficacy of IV iron products, how they are perceived in the community, and barriers to their use in the clinic.
In this “How I Treat” feature from Blood, the authors conclude with 3 representative cases to both illustrate the application of the outlined diagnostic schema and discuss common management considerations, specifically the selection of anticoagulation vs antiplatelet therapy for secondary prevention.